Implantable Cardioverter-Defibrillator Therapy in Brugada Syndrome A 20-Year Single-Center Experience by Conte, Giulio et al.
J O U R N A L O F T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y V O L . 6 5 , N O . 9 , 2 0 1 5
ª 2 0 1 5 B Y T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N DA T I O N I S S N 0 7 3 5 - 1 0 9 7 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j a c c . 2 0 1 4 . 1 2 . 0 3 1Implantable Cardioverter-Deﬁbrillator
Therapy in Brugada Syndrome
A 20-Year Single-Center ExperienceGiulio Conte, MD,* Juan Sieira, MD,* Giuseppe Ciconte, MD,* Carlo de Asmundis, MD,* Gian-Battista Chierchia, MD,*
Giannis Baltogiannis, MD,* Giacomo Di Giovanni, MD,* Mark La Meir, MD,y Francis Wellens, MD,y Jens Czapla, MD,y
Kristel Wauters, MD,* Moises Levinstein, MD,* Yukio Saitoh, MD,* Ghazala Irfan, MD,* Justo Julià, MD,*
Gudrun Pappaert, RN,* Pedro Brugada, MD*ABSTRACTFro
UZ
So
an
Lis
Yo
MaBACKGROUND Patients with Brugada syndrome and aborted sudden cardiac death or syncope have higher risks for
ventricular arrhythmias (VAs) and should undergo implantable cardioverter-deﬁbrillator (ICD) placement. Device-based
management of asymptomatic patients is controversial. ICD therapy is associated with high rates of inappropriate shocks
and device-related complications.
OBJECTIVES The objective of this study was to investigate clinical features, management, and long-term follow-up of
ICD therapy in patients with Brugada syndrome.
METHODS Patients presenting with spontaneous or drug-induced Brugada type 1 electrocardiographic ﬁndings, who
underwent ICD implantation and continuous follow-up at a single institution, were eligible for this study.
RESULTS A total of 176 consecutive patients were included. During a mean follow-up period of 83.8  57.3 months,
spontaneous sustained VAs occurred in 30 patients (17%). Eight patients (4.5%) died. Appropriate ICD shocks occurred in
28 patients (15.9%), and 33 patients (18.7%) had inappropriate shocks. Electrical storm occurred in 4 subjects (2.3%).
Twenty-eight patients (15.9%) experienced device-related complications. In multivariate Cox regression analysis, aborted
sudden cardiac death and VA inducibility on electrophysiologic studies were independent predictors of appropriate shock
occurrence.
CONCLUSIONS ICD therapy was an effective strategy in Brugada syndrome, treating potentially lethal arrhythmias in
17% of patients during long-term follow-up. Appropriate shocks were signiﬁcantly associated with the presence of
aborted sudden cardiac death but also occurred in 13% of asymptomatic patients. Risk stratiﬁcation by electrophysiologic
study may identify asymptomatic patients at risk for arrhythmic events and could be helpful in investigating syncope not
related to VAs. ICD placement is frequently associated with device-related complications, and rates of inappropriate
shocks remain high regardless of careful device programming. (J Am Coll Cardiol 2015;65:879–88) © 2015 by the
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ABBR EV I A T I ON S
AND ACRONYMS
AF = atrial ﬁbrillation
BS = Brugada syndrome
CI = conﬁdence interval
ECG = electrocardiographic
EPS = electrophysiologic study
HR = hazard ratio
ICD = implantable
cardioverter-deﬁbrillator
SCD = sudden cardiac death
SND = sinus node dysfunction
VA = ventricular arrhythmia
VF = ventricular ﬁbrillation
VT = ventricular tachycardia
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880are considered to be the patients with BS at
higher risk for recurrent arrhythmic events
during follow-up, are the best candidates to
undergo ICD therapy (3,4). However, al-
though appropriate ICD therapies are more
prevalent in symptomatic patients, they are
not insigniﬁcant in asymptomatic ones (5).
To date, risk assessment of patients with
asymptomatic BS has not been well estab-
lished, and device-based management in this
setting remains controversial.
Data on long-term follow-up (>6 years) of
patients with BS with ICDs are sparse. In our
previous study, 15% of 47 patients who un-
derwent primary prophylactic ICD therapy
experienced appropriate interventions during
a 4-year follow-up period (6). But ICD im-plantation was not without problems, including high
rates of inappropriate shocks and device-related
complications.SEE PAGE 889The purpose of this study was to analyze our
single-center experience with ICD therapy in patients
with BS over the past 20 years, since the ﬁrst
description of the syndrome. Particularly, we aimed
to assess the clinical features and the long-term
follow-up of patients with BS who underwent ICD
placement and the evolution of device-based man-
agement over the past 2 decades.
METHODS
STUDY POPULATION. Since 1992, all consecutive pa-
tients diagnosed with BS have been included in a
registry and followed in a prospective fashion. The
ethics committee of UZ Brussel-VUB approved the
study protocol. A total of 524 patients with BS were
included in the registry from 1992 to 2012. Among
them, 181 patients (34.5%) received ICD therapy.
Study inclusion criteria consisted of 1) spontaneous or
drug-induced Brugada type 1 electrocardiographic
(ECG) pattern, (2) ICD implantation, and (3) contin-
uous follow-up at our institution. One-hundred
seventy-six patients (97.2%) fulﬁlled the inclusion
criteria. Five patients (2.8%) were not included
because of a follow-up time of <6 months. Medical
history, physical examination, and baseline elec-
trocardiography were performed, and underlying
structural cardiac abnormalities were excluded in
all patients. All patients with syncope before
receiving ICDs underwent careful diagnostic work-up
for arrhythmic origins of the events. The work-up
included a careful examination of the patient’shistory, 12-lead electrocardiography, transthoracic
echocardiography, and Holter monitoring. Electro-
physiologic study (EPS) was performed in patients
with syncope potentially related to supraventricular
arrhythmias. Arrhythmic syncope was suspected in
the absence of prodromes and speciﬁc triggering
circumstances and in the presence of brief loss of
consciousness and rapid return to consciousness or
severe trauma. A tilt-table test was performed in
patients with suspected vasovagal syncope. ECG pat-
terns were classiﬁed as Brugada coved type (type 1) or
saddleback (type 2) or normal. An electrocardiogram
was considered diagnostic of BS if a coved-type ST-
segment elevation of $2 mm was documented in $1
lead from V1 to V3 in the presence or absence of a
sodium-channel blocker. Abnormal fragmentation of
the QRS complex was deﬁned as the presence of
multiple spikes within the QRS complex ($4 spikes in 1
lead or $8 spikes in leads V1, V2, and V3) (7). All base-
line and drug-induced 12-lead electrocardiograms
were recorded at a paper speed of 25 mm/s and
amplitude of 10 mm/mV, with the right precordial
leads positioned at the sternal margin of the third and
fourth intercostal space. Two independent experi-
enced electrophysiologists analyzed all electrocar-
diograms; in cases of disagreement, a third physician
was consulted. Patients were considered symptomatic
if they presented with syncope and/or aborted SCD.
EPS was performed at the investigators’ preference to
assess risk stratiﬁcation. Programmed ventricular
stimulation consisted of a maximum of 3 ventricular
extrastimuli with a minimal coupling interval of 200
ms delivered from 1 ventricular site unless ventricular
ﬁbrillation (VF) or sustained ventricular tachycardia
(VT) lasting at least 30 s, accompanied with syncope or
requiring intervention for termination was induced.
Genetic testing with sequence analysis of SCN5A was
recommended for all patients with diagnoses of BS.
AJMALINE CHALLENGE. Ajmaline (1 mg/kg) was
administered intravenously over a 5-min period to
unmask the diagnostic ECG pattern of BS in case of a
nondiagnostic baseline electrocardiogram. The test
was considered positive for BS only if coved-type ECG
pattern was documented in $1 right precordial lead
(V1 to V3). Ajmaline infusion was discontinued before
reaching the target dose if QRS prolongation exceeded
30% compared with the baseline interval, when
frequent premature ventricular beats or Brugada type
1 ECG pattern occurred or in case of development of
high-degree atrioventricular block. Ajmaline-induced
VAs were deﬁned as the occurrence of sustained
episodes of VF or VT.
ICD IMPLANTATION. Beginning in 2005, the indica-
tions for ICD therapy were determined using the
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881recommendations of the second Brugada consensus
conference (4). The decision to perform epicardial or
endocardial lead implantation or to place the device
in a thoracic or subcostal pocket was made according
to the patient’s age, anthropometric characteristics,
and level of physical activity. The choice between
single- and dual-chamber devices was driven by the
presence of previous episodes of supraventricular
arrhythmias or evidence of sinus node dysfunction
(SND). ICD programming at the time of implantation
changed over time. After our initial experience, the
VF detection rate was increased from 180 to more
than 200 beats/min for primary prevention implan-
tations, and a monitor zone was added (6,8). In
accordance with more recently published data, apart
from setting a high cutoff rate, long detection
intervals (30 of 40 intervals) were adopted to avoid
unnecessary therapies (9–11). Conversely, in patients
undergoing ICD therapy for secondary prevention, a
monitor zone (>150 beats/min) and a fast VT zone
(180 to 200 beats/min) with antitachycardia pacing
and shocks were programmed in all cases, and sup-
raventricular tachycardia discriminators were acti-
vated if available. These settings were adjusted
during follow-up on the basis of individual clinical
history and to avoid recurrences of inappropriate
interventions.
FOLLOW-UP. Clinical follow-up of patients consisted
of physical examinations and electrocardiography at
least every 6 months. Follow-up of the device was
performed at 1 and 3 months after implantation and
thereafter every 6 months. Clinical data were regu-
larly collected. From 2006, home monitoring devices
were implanted either de novo or at battery change,
in case of prior implantation, in all patients younger
than 12 years and in 30% of older patients.
Arrhythmic events receiving ICD therapies were
pre-deﬁned according to the cycle lengths of the
arrhythmias. All available electrograms of appro-
priate and inappropriate shocks were analyzed by at
least 2 investigators independently. Electrograms
were derived from various bipolar conﬁgurations
involving the tip and ring electrodes or shocking coils
on the pacing or deﬁbrillating lead or a wide bipolar
recording between one of the ventricular electrodes
and the ICD casing. For primary prevention implan-
tations, the VF detection rate was usually higher than
180 to 200 beats/min (according to the year of
implantation). For these patients, an attempt to
discriminate rapid polymorphic VT and VF was made
when possible on the basis of the electrographic
conﬁguration derived from multiple ICD channels.
Monomorphic VTs were deﬁned as arrhythmias withconstant electrographic conﬁguration and a stable rate
within a few beats. Polymorphic VTs had a changing
rate and demonstrated varying conﬁgurations and
rate between 180 and 200 beats/min. Conversely, an
arrhythmia was characterized as VF if the cycle length
was irregular and had a rate higher than 200 beats/min
and/or occurred in the presence of electrograms of
continuously varying conﬁguration.
Appropriate therapies were deﬁned as shocks or
antitachycardia pacing delivered for VT or VF, and
inappropriate therapies were deﬁned as those deliv-
ered in the absence of VAs. Electrical storm was
deﬁned by 3 or more sustained episodes of VT, VF, or
appropriate ICD shocks within 24 h.
STATISTICAL ANALYSIS. Data are presented as
mean  SD or as absolute values and percents as
appropriate. Comparisons between continuous vari-
ables were performed using the unpaired Student t
test or analysis of variance as appropriate. The chi-
square test was used to compare categorical vari-
ables. Event-free survival was estimated by the
Kaplan-Meier method and compared by the log-rank
test. Hazard ratios (HRs) were calculated using Cox
proportional hazards regression models. Cox regres-
sion analysis was used for the predictor model.
Variables were selected on the basis of univariate
signiﬁcance and/or if they were known predictors in
published research. The ﬁnal model was selected by
stepwise regression on the basis of likelihood ratios. A
p value of <0.05 was considered to indicate statistical
signiﬁcance. Statistical analyses were conducted
using SPSS version 22 (SPSS, Inc., Chicago, Illinois).
RESULTS
BASELINE CHARACTERISTICS. A total of 176
consecutive patients (118 male [67%]; mean age
43.3  16.8 years; range: 2 to 77 years) received ICDs
at our institution from 1992 to 2012 and met the in-
clusion criteria for this study. Baseline clinical and
procedural characteristics of the study population are
shown in Table 1. Patients belonged to 92 different
families. At the time of implantation, 19 patients
(10.8%) were younger than 18 years. Family histories
of SCD were present in 90 patients (51%). Twenty-ﬁve
subjects (14.2%) presented with aborted SCD before
ICD placement. One-hundred ﬁve patients (59.7%)
had at least 1 episode of syncope, and 46 (25.1%) were
completely asymptomatic before receiving ICDs.
Twenty-four patients (13.6%) had documented epi-
sodes of sustained atrial arrhythmias (atrial ﬁbrilla-
tion [AF] or atrial ﬂutter). Moreover, 9 patients (5.1%)
presented with SND. Spontaneous Brugada type 1
ECG pattern was documented in 37 patients (21%).
TABLE 1 Baseline Clinical and Procedural Characteristics of the Study Population
According to Year of Implantation
Overall
(n ¼ 176)
Group I
(n ¼ 82)
Group II
(n ¼ 94) p Value
Age, yrs 43.3  16.8 42.5  15.3 44.0  18.2 0.46
Male 118 (67.0) 62 (75.6) 56 (59.6) 0.02
Spontaneous type 1 ECG pattern 37 (21.0) 28 (34.1) 9 (9.6) <0.01
Aborted SCD 25 (14.2) 15 (18.3) 10 (10.6) 0.15
Syncope 105 (59.7) 39 (47.6) 66 (70.2) <0.01
Asymptomatic 46 (26.1) 28 (34.1) 18 (19.1) 0.01
Family history of SCD 90 (51.1) 47 (57.3) 43 (45.7) 0.13
Previous atrial arrhythmias 24 (13.6) 14 (17.1) 10 (10.6) 0.22
Previous SND 9 (5.1) 6 (7.3) 3 (3.2) 0.31
Inducible on EPS* 72 (43.6) 58 (75.3) 14 (15.9) <0.01
SCN5A mutation* 23 (21.9) 13 (21.7) 10 (22.2) 0.95
Abdominal implantation 19 (10.8) 6 (7.3) 13 (13.8) 0.19
Epicardial lead placement 8 (4.5) 3 (3.7) 5 (5.3) 0.73
Values are mean  SD or n (%). Group I included patients who underwent ICD placement before 2005, and group
II included patients who underwent ICD placement during or after 2005. *Percents refer to patients who
underwent EPS and genetic testing.
ECG ¼ electrocardiographic; EPS ¼ electrophysiologic study; ICD ¼ implantable cardioverter-deﬁbrillator;
SCD ¼ sudden cardiac death; SND ¼ sinus node dysfunction.
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the remaining 139 patients (79%). Among them,
9 patients (6.5%) experienced drug-induced sus-
tained VAs. EPS was performed in 165 patients
(93.7%). Sustained VAs were induced during pro-
grammed ventricular stimulation in 72 patients
(43.6%). A total of 105 genetic tests (59.7%) were
performed; 23 of them (21.9%) were positive for
mutations in the SCN5A gene.
The clinical proﬁle of the patients who received
ICDs during the 20-year study period changed over
time (Table 1). In particular, the rate of asymptomatic
patients signiﬁcantly decreased after 2005 (from
34.1% before 2005 to 19.1% during or after 2005;
p ¼ 0.01). Similarly, there was a signiﬁcant reduction
in the number of patients with inducible arrhythmias
during EPS (from 75.3% before 2005 to 15.9% during
or after 2005; p < 0.01). Conversely, the rate of
patients with syncope increased (from 47.6% before
2005 to 70.2% during or after 2005; p < 0.01). No
signiﬁcant temporal difference was found in the
number of patients presenting with aborted SCD or in
those with family histories of SCD in whom ICDs were
placed before or after 2005. Moreover, the number of
patients with spontaneous Brugada type 1 ECG
pattern undergoing ICD placement decreased over
time (from 34.1% before 2005 vs. 9.6% during or after
2005; p < 0.01).
SYMPTOM STATUS. A total of 130 patients (73.8%)
presented with syncope and/or aborted SCD before
ICD implantation. The remaining 46 patients wereasymptomatic. Clinical characteristics of patients ac-
cording to their symptom status are shown in Table 2.
No signiﬁcant difference was found in the clinical
features among patients presenting with syncope and
aborted SCD and asymptomatic patients.
Aborted SCD. Twenty-ﬁve patients (14.2%) pre-
sented with previous episodes of aborted SCD due to
spontaneous sustained VAs. Sixteen (64%) were
male, and 10 (40%) had family histories of SCD.
Spontaneous Brugada type 1 ECG pattern was docu-
mented in 7 patients (28%). The mean age at the time
of SCD was 39.5  15.6 years, ranging from 6 days to 61
years. One infant and 1 child experienced multiple
episodes of aborted SCD before reaching 2 years of
age. Aborted SCD was the ﬁrst clinical manifestation
of the syndrome in 20 patients (11.3%). SCD was pre-
ceded by episodes of syncope and by palpitations in 4
patients and 1 patient, respectively. Sudden death
occurred at rest in 16 patients, during exercise in 5,
during sleep in 3, and during a febrile episode in 1.
Syncope. Syncope was the clinical manifestation of
the syndrome in 105 patients (59.7%). Sixty-six
(62.8%) were male, and 53 (50.4%) had family
histories of SCD. Forty-eight patients (45.7%) were
family members of patients with BS. Spontaneous
Brugada type 1 ECG pattern was documented in 19
patients (18.1%). The mean age at the time of ﬁrst
syncope was 43.2  17.2 years. The mean number of
episodes of syncope per patient was 1.2  0.8. Syn-
cope occurred at rest in 72 patients (68.6%) and dur-
ing exercise in 27 subjects (25.7%). Syncope was
associated exclusively with fever in 6 patients (5.7%).
Asymptomat i c pat ients . Forty-six patients (26.1%)
did not report any symptoms before receiving ICDs.
Twenty-seven (58.7%) were family members of BS
patients. Indications for ICD therapy in these patients
were: 1) the presence of spontaneous Brugada type 1
ECG pattern and family history of SCD in 2 patients
(4.3%); 2) spontaneous Brugada type 1 ECG pattern
and sustained VA induced during EPS in 9 patients
(19.6%); and 3) sustained VA during ajmaline chal-
lenge in 5 patients (10.9%). The remaining 30 patients
(65.2%) received ICDs because of ajmaline-induced
Brugada type 1 ECG pattern with sustained VA
induced during EPS (n ¼ 17) or family histories of SCD
(n ¼ 13).
PROCEDURAL CHARACTERISTICS. One-hundred nine
patients (62%) received single-chamber transvenous
devices, and 59 (33.5%) underwent dual-chamber
transvenous ICD implantation. Single and dual
epicardial leads were implanted in 6 and 2 patients
(4.5%), respectively. No patient received a totally
subcutaneous system. Nineteen subjects (10.8%)
TABLE 2 Clinical Characteristics and Outcomes of Patients According to ICD Indication
Overall
(n ¼ 176)
Aborted SCD
(n ¼ 25)
Syncope
(n ¼ 105)
Asymptomatic
(n ¼ 46) p Value
Clinical features
Age, yrs 43.3  16.8 39.5  15.6 43.2  17.2 45.3  16.6 0.41
Male 118 (67.0) 16 (64.0) 66 (62.9) 36 (78.3) 0.17
Proband 92 (52.3) 16 (64.0) 57 (54.3) 19 (41.3) 0.15
Spontaneous type 1 ECG
pattern
37 (21.0) 7 (28.0) 19 (18.1) 11 (23.9) 0.47
Family history of SCD 90 (51.1) 10 (40.0) 53 (50.5) 27 (58.7) 0.32
Previous atrial
arrhythmias
24 (13.6) 3 (12.0) 14 (13.3) 7 (15.2) 0.92
Previous SND 9 (5.1) 1 (4.0) 5 (4.8) 3 (6.5) 0.87
Inducible on EPS* 72 (43.6) 5 (26.3) 39 (37.9) 28 (65.1) <0.01
SCN5A mutations* 23 (21.9) 6 (26.1) 9 (15.8) 8 (32) 0.23
Outcomes
Appropriate shocks 28 (15.9) 11 (44.0) 11 (10.5) 6 (13.0) <0.01
Time to ﬁrst
therapy, months
20.7  25.9 23.6  32.5 19.9  18.5 15.7  28.3 0.85
Shock rate per year 0.46  1.05 0.23  0.28 0.8  1.56 0.16  0.11 0.38
Inappropriate shocks 33 (18.8) 8 (32.0) 18 (17.1) 7 (15.2) 0.54
Time to ﬁrst
therapy (months)
49.9  46.2 53.9  47.6 54.8  50.4 34.2  36.8 0.66
Shock rate per year 0.47  1.26 0.19  0.19 0.64  1.59 0.17  0.05 0.71
Deaths 8 (4.5) 3 (12.0) 5 (4.8) 0 (0) 0.10
Values are mean  SD or n (%). *Percents refer to patients who underwent EPS and genetic testing.
Abbreviations as in Table 1.
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883underwent abdominal pulse generator placement.
Mean R-wave amplitude at implantation was 11.3 
4.7 mV. After ICD implantation, 4 patients (2.3%)
experienced device-related early complications: 2
pneumothoraxes, 1 episode of pericarditis that
occurred 1 month after epicardial lead placement, and
a dislocation of the abdominal generator that led to
the revision of the device 1 week after implantation.
LONG-TERM FOLLOW-UP. After a mean follow-up
period of 83.8  57.3 months, spontaneous sus-
tained VAs were documented in 30 patients (17%).
Sustained VA was terminated by ICD shocks in 28
patients (15.9%) and by antitachycardia pacing in 2
patients (1.1%). Thirty-three patients (18.7%) experi-
enced inappropriate shocks. Electrical storm occurred
in 4 subjects (2.3%). Nonsustained VAs were docu-
mented in 10 patients (5.7%). Of note, 30 patients
(21.6%) with drug-induced BS presented with spon-
taneous Brugada type 1 ECG pattern during follow-up.
Spontaneous Brugada type 1 ECG pattern could be
documented on at least 1 occasion during the follow-
up period in 67 patients (38.1%). After ICD placement,
21 patients (11.9%) experienced episodes of syncope.
Of them, 5 patients had neurally mediated syncope.
In 8 patients with recurrent syncope after ICD im-
plantation, the rate of ventricular pacing was <1%,
and no VAs were detected. Among initially asymp-
tomatic patients, 3 (6.5%) experienced syncope dur-
ing follow-up. Thirty-two patients (18.2%) developed
paroxysmal AF: 6 in the asymptomatic group, 21
(20%) in the syncope group, and 5 (20%) in the
aborted SCD group (p ¼ 0.58). Six patients (3.4%) with
ICDs and drug-resistant AF underwent pulmonary
vein isolation by means of radiofrequency energy
source (n ¼ 5) or cryoballoon ablation (1 patient). At
last follow-up, a total of 19 patients (10.8%) with
documented atrial arrhythmias were under pharma-
cological treatment with sotalol or beta-blockers.
Fifty-two patients (29.5%) underwent generator
replacement. The mean number of battery changes
during the follow-up was 1.27  0.5 per patient.
MORTALITY. Eight patients (4.5%) died during
follow-up. The mean age at death was 55.7 
20.7 years. The mean time from BS diagnosis to death
was 8.1  4.9 years. Cardiac death occurred in
3 patients. One subject died in the hospital because of
cardiogenic shock complicating an acute anterolateral
wall myocardial infarction that presented with
persistent ST-segment elevation. Another patient
experienced septic shock with fatal consequences
shortly after device revision. A third patient died as
consequence of an arrhythmic event (Central
Illustration). He was the ﬁrst patient ever diagnosedwith BS. He had presented at 3 years of age with
syncope and recurrent aborted SCDs and had
concomitant SND and AF and atrial ﬂutter. He ﬁrst
received a pacemaker and pharmacologic therapy
with amiodarone, beta-blockers, digoxin, and diphe-
nylhydantoin but had 2 further episodes of syncope.
Subsequently, he was asymptomatic for 13 years, at
which point the family agreed to undergo ICD im-
plantation. After the implantation, antiarrhythmic
therapy was discontinued. The patient died suddenly
11 months after ICD implantation, at 18 years of age,
because of VF refractory to both internal and external
deﬁbrillations. In the remaining 5 cases, death was
due to noncardiac causes. None of the asymptomatic
patients died.
APPROPRIATE SHOCKS. Twenty-eight patients (15.9%)
experienced at least 1 appropriate shock during the
follow-up period (Central Illustration). Twenty-four
(85.7%) were male, and 22 (78.6%) were symptom-
atic. Six patients (21.4%) had neither aborted SCD
nor previous syncope. Of note, appropriate shocks
occurred in 13% of asymptomatic patients. However,
the rate of appropriate shocks was signiﬁcantly higher
in patients presenting with aborted SCD compared
with the other patients (p < 0.01) (Table 2). Sixteen of
these patients (53.6%) presented with spontaneous
CENTRAL ILLUSTRATION ICD Therapy in Brugada Syndrome
Kaplan-Meier curve analyzing freedom from appropriate shocks according to
implantable cardioverter-deﬁbrillator (ICD) indication. SD ¼ sudden cardiac death.
TABLE 3
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884Brugada type 1 ECG pattern. The median time to ﬁrst
therapy was 11.6 months (interquartile range: 5.3 to
33.0 months). The mean number of shocks delivered
per patient was 2.1  2.8. Seventeen patients (60.7%)
had 1 shock, 6 (21.4%) experienced 2 shocks, andUnivariate Cox Regression Analysis Among Patients Experiencing
te Shocks
b Coefﬁcient HR (95% CI) p Value
0.02 0.98 (0.96–1.0) 0.12
1.08 2.95 (1.02–8.53) 0.04
0.35 0.71 (0.33–1.53) 0.38
us type 1 ECG pattern 0.91 2.50 (1.16–5.39) 0.02
0.97 2.63 (1.40–4.92) <0.01
0.08 0.93 (0.32–2.67) 0.89
SCD 1.51 4.53 (1.57–13.0) <0.01
tory of SCD 0.42 0.66 (0.31–1.42) 0.29
F 0.31 0.73 (0.22–2.44) 0.61
ND 0.57 1.77 (0.42–7.50) 0.44
ibility 0.90 2.44 (1.18–6.02) 0.04
tation 0.29 1.33 (0.24–7.45) 0.74
on during or after 2005 1.18 0.31 (0.12–0.77) 0.01
age considers every year increase.
al ﬁbrillation; CI ¼ conﬁdence interval; HR ¼ hazard ratio; other abbreviations as in5 (17.9%) received 3 or more shocks. Twenty-two pa-
tients received ICD shocks for VF and 3 for poly-
morphic VT. ICD therapy was delivered for
monomorphic VT in the remaining 3 patients. All VF
and VT episodes had ventricular rates higher than 200
and 180 beats/min, respectively.
On univariate analysis, male sex (HR: 2.95; 95%
conﬁdence interval [CI]: 1.02 to 8.53; p ¼ 0.04),
spontaneous Brugada type 1 ECG pattern (HR: 2.50;
95% CI: 1.16 to 5.39; p ¼ 0.02), aborted SCD (HR: 4.53;
95% CI: 1.57 to 13.0; p < 0.01), and VA inducibility on
EPS (HR: 2.44; 95% CI: 1.18 to 6.02; p ¼ 0.04) were
shown to confer a higher risk for experiencing an
appropriate shock during follow-up. Implantation
after 2005 was shown to be a protective factor (HR:
0.31; 95% CI: 0.12 to 0.77; p ¼ 0.01) (Table 3). Aborted
SCD (HR: 5.13; 95% CI: 2.03 to 12.96; p < 0.01) and VA
inducibility on EPS (HR: 3.38; 95% CI: 1.33 to 8.59;
p ¼ 0.01) remained the only signiﬁcant predictors of
appropriate shocks on multivariate analysis.
ELECTRICAL STORM. Four patients (2.3%) presented
with electrical storm during the follow-up period
(Table 4, Figure 1). Three were male (75%). The mean
age at the time of electrical storm was 41  10 years.
Electrical storm occurred 2.9  2.6 years after ICD
implantation. Aborted SCD was the indication for ICD
therapy in all patients. Two patients had experienced
episodes of appropriate shocks 3 and 5 years before
the occurrence of electrical storm. After the electrical
storm, 2 patients were treated with quinidine with no
further arrhythmic recurrences, and 1 patient under-
went VF ablation with no subsequent episodes of
electrical storm. The remaining patient who experi-
enced another episode of electrical storm underwent
heart transplantation.
INAPPROPRIATE SHOCKS. Thirty-three patients (18.7%)
had inappropriate shocks a median of 36.9 months
(interquartile range: 9.4 to 75.4 months) after ICD
implantation. The mean number of inappropriate
shocks delivered per patient was 3.0  5.7. Eighteen
patients (54%) experienced 1 shock, and 15 had 2 or
more episodes of inappropriate shocks (46%). Inap-
propriate shocks were due to sinus tachycardia in
5 patients, noise on the ventricular channel after lead
fracture in 7 patients, and T-wave oversensing in
6 patients. The remaining 15 subjects experienced
inappropriate shocks because of episodes of AF
with fast ventricular rate. Among these patients, 3
underwent pulmonary vein isolation because of drug-
resistant paroxysmal AF. At follow-up, the remaining
12 patients were under pharmacological treatment
with sotalol (n ¼ 10) or beta-blockers and sotalol
(n ¼ 2). Conversely, none of the patients who
TABLE 4 Clinical Characteristics of Patients Experiencing Electrical Storm
Patient # Sex Age (yrs) Proband
Family
History of
SCD
Spontaneous
Type 1 ECG
Pattern ICD Indication f-QRS
1 Male 34 No Yes Yes Aborted SCD No
2 Male 24 No Yes Yes Aborted SCD No
3 Male 53 Yes No No Aborted SCD Yes
4 Female 41 No No No Aborted SCD No
f-QRS ¼ fragmentation of QRS complex; other abbreviations as in Table 1.
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885experienced inappropriate shocks because of sinus
tachycardia were treated pharmacologically. Of note,
the incidence of inappropriate shocks did not differ
depending on patients’ previous symptom status
(Table 2).
DEVICE-RELATED COMPLICATIONS. During follow-
up, 28 patients (15.9%) experienced device-related
complications. Twenty-one (75%) were younger than
40 years at the time of implantation. Complications
consisted of fracture of the ventricular electrode
and subsequent extraction and replacement in
14 patients, lead dislocation in 7 patients, and pulse
generator migration in 2 patients, leading to revision
of the device in all patients. The other 5 patients had
device infections, which led to replacement of the
devices.FIGURE 1 Baseline Electrocardiograms of Patients With Electrical St
Fragmentation of the terminal portion of the QRS complex can be appr
ajmaline challenge. Pt ¼ patient.DISCUSSION
CLINICAL PROFILE OF PATIENTS WITH BS WHO
RECEIVE ICDs. Patients presenting with either
symptomatic or asymptomatic BS are usually in theirorm
eciated in all leads of the baseline electrocardiogram of Patient #3. *Electrocardiogram after
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886fourth or ﬁfth decade of life (3), and in our study, pa-
tients with BS receiving ICDs presented with a mean
age of 40 years. Most were male, and 74% were
symptomatic, presenting with aborted SCD or syncope
before ICD placement. Interestingly, the clinical pro-
ﬁle of patients undergoing ICD therapy changed dur-
ing the 20-year study period, particularly after the
second Brugada consensus conference recommenda-
tions (4). The rate of asymptomatic patients signiﬁ-
cantly decreased after 2005 (from 34.1% to 19.1%),
and there was a signiﬁcant reduction in the number
of patients with inducible arrhythmias during EPS
(from 75.3% to 15.9%). Conversely, the rate of pa-
tients with syncope increased (from 47.6% to 70.2%).
No signiﬁcant temporal difference was found in the
number of patients presenting with aborted SCD or in
those with family histories of SCD. Although it has a
psychological impact for patients and their families,
family history of SCD has not been shown to be pre-
dictive of future arrhythmic events in patients with
BS, and it does not appear to be of prognostic value in
patients with ICDs (12). Thus, asymptomatic patients
with family histories of SCD do not have an indication
for ICD placement on that basis alone. Clinical follow-
up with electrocardiography should be performed
every 6 months in these patients, and EPS should be
considered for risk stratiﬁcation purposes. Of note,
the rate of patients with spontaneous Brugada type 1
ECG pattern undergoing ICD placement decreased
over time (from 34.1% to 9.6%). This could be
explained by a more proactive attitude developed
after 2005 in the diagnosis of the syndrome in pa-
tients with syncope and in asymptomatic family
members.
APPROPRIATE SHOCKS. An important ﬁnding of the
present study concerns the considerable risk for SCD
during long-term follow-up, affecting patients with
BS with ICDs for primary or secondary prevention. In
our study, 17% of patients experienced documented
life-threatening arrhythmias during a mean follow-up
period of 7 years. Moreover, 1 patient died because of
an arrhythmic event. The rate of appropriate shocks
was 16%. The discharge rate was comparable to the
rate reported in our previous follow-up study (14.9%)
conducted in patients undergoing ICD implantation
for prophylactic purposes only (6). This previous
study was not able to identify any independent pre-
dictors of future arrhythmic events, possibly because
of the relatively low event rate in a small patient
population. In the present study, including a larger
number of patients, aborted SCD (HR: 5.13) and VA
inducibility on EPS (HR: 3.38) were found to be the
only independent predictors of appropriate shocks inmultivariate analysis. Moreover, in univariate anal-
ysis, apart from aborted SCD and VA inducibility on
EPS, male sex and spontaneous Brugada type 1 ECG
pattern were shown to confer a higher risk for expe-
riencing an appropriate shock during follow-up.
Although the device-based therapeutic management
of BS in asymptomatic patients is challenging, the
decision to implant an ICD after an episode of aborted
SCD is straightforward. In our study, the appropriate
device therapy rate at 7 years was 44% in patients in
whom the ICD therapy indication was aborted SCD.
Previously, Sacher et al. (5) reported a similar rate of
appropriate shocks after ICD therapy for secondary
prevention. Although low, the rate of sustained VA in
asymptomatic patients with ICD has been reported as
0.81% per year (5). Of note, in our study, it was not as
low as previously thought, affecting 13% of previ-
ously asymptomatic patients. In patients without
histories of VT or VF, the identiﬁcation of potential
predictors of arrhythmic events during follow-up has
been assessed in different studies, with controversial
results, and the role of EPS has been considered
questionable. Data from the PRELUDE (Programmed
Electrical Stimulation Predictive Value) study identi-
ﬁed the presence of spontaneous Brugada type 1 ECG
pattern and history of syncope as the only signiﬁcant
predictors of arrhythmias (13). Conversely, the pres-
ence of VT or VF inducibility on EPS failed to identify
patients at risk for developing arrhythmic events
during follow-up (13). In our study, VA inducibility
during EPS appeared to confer a signiﬁcantly higher
risk for experiencing appropriate shocks during
follow-up. Therefore, risk assessment on the basis of
clinical features, such as male sex, baseline electro-
cardiography, or the results of EPS, should be always
taken into account when considering ICD therapy.
Moreover, EPS might be valuable in the clinical
evaluation of patients with syncope to rule out the
presence of SND or supraventricular arrhythmias as
potential causes of the event. Interestingly, in the
present study, syncope was not found to be an inde-
pendent predictor of future VAs, and freedom over
time from appropriate shocks did not differ between
asymptomatic patients and those with syncope
(Figure 1). Despite performing a proper diagnostic
work-up, in some cases, it remains difﬁcult to
determine whether syncope is truly due to VA. All
large registries of patients with BS and syncope
report that 6% to 19% of patients experience
arrhythmic events during follow-up of 24 to 39
months (5,6,8). In our study, 11% of patients with
syncope received appropriate shocks. Currently, ICD
therapy is considered in order to prevent SCD in
patients presenting with episodes of syncope if no
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887other cause of syncope is found (4). The decision to
perform ICD implantation in this setting must be
taken after a careful evaluation of the episode, as in
this category of patients, it is not always easy to
differentiate its origin. In our study, 8% of patients
with syncope experienced further episodes of syn-
cope during follow-up, but no VA was detected by
the device. Moreover, 18% of patients developed
paroxysmal AF. It has been shown that approxi-
mately 20% of patients with BS can develop supra-
ventricular arrhythmias that can be a potential cause
of syncope (14). Similarly, a prolonged sinus node
recovery time and sinoatrial conduction time as
well as slowed atrial conduction and atrial standstill
have been reported in association with the syn-
drome and can lead to syncope (15). Thus, in any
case of syncope suspected to be attributable to
arrhythmic causes other than VAs, an EPS should be
always performed to clarify the diagnosis before ICD
implantation.
Interestingly, 2% of our study population presented
with electrical storm during follow-up, requiring
drug therapy initiation, ablation, or cardiac trans-
plantation. Electrical storm occurrence is always a
tragic event, even more so when the patient is young.
Pharmacologic therapy aimed at rebalancing the cur-
rents active during the early phases of the epicardial
right ventricular action potentials can be useful to
abort electrical storms. In particular, drugs such as
quinidine inhibit the transient outward current, acting
to diminish the action potential notch and thus sup-
press the substrate and trigger for VAs (16).
ADVERSE EFFECTS OF ICD THERAPY. Inappropriate
shocks are among the most important adverse effects
of ICD therapy. In our study, 18.7% of patients expe-
rienced inappropriate shocks due to supraventricular
arrhythmias, lead fracture, and T-wave oversensing.
The frequency of inappropriate shocks in our study is
consistent with the data previously reported by other
groups. Steven et al. (17) reported a 15% rate of
inappropriate shocks in series of 33 patients at 8-year
follow-up. Similarly, Sacher et al. (5) reported inap-
propriate shocks in 24% of patients during 6-year
follow-up. On the basis of the results of our previ-
ous study (6), in 2006 we started to program a single
VF zone with a lower detection rate (>200 beats/min)
in patients younger than 50 years and to adjust these
settings on the basis of the individual clinical history.
However, in this study, no signiﬁcant temporal dif-
ference was found in terms of the rate of inappro-
priate shocks between patients implanted before
or after 2005 (implantation after 2005: HR: 1.1;
95% CI: 0.43 to 2.78; p ¼ 0.83). Young age, an activeproﬁle, and the predisposition of these patients to
atrial arrhythmias likely increase the risk for inap-
propriate shocks. Moreover, the incidence of atrial
arrhythmias has been reported to be higher in
patients with ICDs (27%) compared with those
without indications for ICD (13%), suggesting a more
advanced disease process in patients with sponta-
neous atrial arrhythmias (18). Apart from setting high
rate cutoffs, a strategy to reduce unnecessary thera-
pies might be the insertion of a high VT zone with
supraventricular tachycardia discriminators and a
prolonged delay in therapy delivery by increasing the
number of intervals to detect (11,19,20).
Patients with BS with ICDs have already been
demonstrated to be more difﬁcult to manage, not
only because of the high incidence of inappropriate
therapies but also because of their long life expec-
tancy compared with the conventional ICD patient
population, in which lead failure rates have been re-
ported to range from 15% to 40% after 5 and 8 years,
respectively (21). In this study, the rate of device-
related complications was 16% at 7-year follow-up,
and 75% of patients were younger than 40 years. It
is well established that ICD placement in patients
with BS is not without potential problems (5,6). Of
note, in a previous study from our group, complica-
tions affected up to 33% of children with ICDs (22). In
this particularly active category of patients, lead
fracture can more frequently occur. Moreover, their
long life expectancy leads to multiple generator
change procedures, with a potential increased rate of
device-related complications. Finally, lead-related
problems can give rise to inappropriate therapies,
with a signiﬁcant impact on the quality of life of pa-
tients and relatives.
STUDY LIMITATIONS. Our study was a single-center
experience conducted in a population of patients
with heterogeneous clinical characteristics. The na-
ture of this analysis, conducted on ICD implantations
performed over 20 years, was retrospective. Thus, the
ICD programming evolution over this period of time
and the lack of consistent or pre-speciﬁed settings
might be limitations of the study. EPS with pro-
grammed ventricular stimulation and genetic testing
were not performed in all patients. Furthermore, in
patients with lifelong risk for arrhythmias, a mean
follow-up period of 7 years might be too short.
CONCLUSIONS
ICD therapy was an effective strategy in patients with
BS, treating potentially lethal arrhythmias in 17%
of patients during long-term follow-up. Appro-
priate shocks were signiﬁcantly associated with the
PERSPECTIVES
COMPETENCY IN INTERPERSONAL AND
COMMUNICATION SKILLS: Before the implanta-
tion of ICDs, physicians should explain to patients
with BS the potential beneﬁts and risks of device-
related complications.
TRANSLATIONAL OUTLOOK: Longer term follow-
up studies are needed to better identify patients with
BS prone to developing life-threatening arrhythmias
and to clarify the value of diagnostic electrophysio-
logic testing.
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888presence of aborted SCD, but they also occurred in
13% of asymptomatic patients. On the basis of our
ﬁndings, risk stratiﬁcation by means of EPS might
identify asymptomatic patients at risk for arrhythmic
events and could be helpful in investigating syncope
potentially not related to VA. ICD placement is
frequently associated with device-related complica-
tions, affecting 16% of patients. Moreover, inappro-
priate shock rates remain high regardless of careful
device programming.
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